• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Myovant Sciences Ltd. (Amendment)

    2/10/22 5:36:04 PM ET
    $MYOV
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MYOV alert in real time by email
    SC 13G/A 1 myov2102022.txt JANUS HENDERSON GROUP PLC OWNS >5% UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Amendment No.: 2* Name of Issuer: Myovant Sciences Ltd. Title of Class of Securities: Common Stock CUSIP Number: G637AM102 Date of Event Which Requires Filing of this Statement: 12/31/2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed. [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No.: G637AM102 1. NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON Janus Henderson Group plc EIN #00-0000000 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP a. ___ b. ___ 3. SEC USE ONLY 4. CITIZENSHIP OR PLACE OF ORGANIZATION Jersey, Channel Islands NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH: 5. SOLE VOTING POWER 0** 6. SHARED VOTING POWER 5,527,464** 7. SOLE DISPOSITIVE POWER 0** 8. SHARED DISPOSITIVE POWER 5,527,464** 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 5,527,464** 10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES Not applicable 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 5.9%** 12. TYPE OF REPORTING PERSON IA, HC ** See Item 4 of this filing Item 1. (a). Name of Issuer: Myovant Sciences Ltd. ("Myovant") (b). Address of Issuer's Principal Executive Offices: Suite 1, 3rd Floor, 11-12 St. James's Square London, SW1Y 4LB United Kingdom Item 2. (a).-(c). Name, Principal Business Address, and Citizenship of Persons Filing: (1) Janus Henderson Group plc 201 Bishopsgate EC2M 3AE, United Kingdom Citizenship: Jersey, Channel Islands (d). Title of Class of Securities: Common Stock (e). CUSIP Number: G637AM102 Item 3. This statement is filed pursuant to Rule 13d-1 (b) or 13d-2(b) and the person filing, Janus Henderson Group plc ("Janus Henderson") is a parent holding company/control person in accordance with Section 240.13d-1(b)(ii)(G). See Item 4 for additional information. Item 4. Ownership The information in items 1 and 5 through 11 on the cover page(s) on Schedule 13G is hereby incorporated by reference. Janus Henderson has an indirect 97% ownership stake in Intech Investment Management LLC ("Intech") and a 100% ownership stake in Janus Henderson Investors U.S. LLC ("JHIUS"), Henderson Global Investors Limited ("HGIL") and Janus Henderson Investors Australia Institutional Funds Management Limited ("JHIAIFML"), (each an "Asset Manager" and collectively as the "Asset Managers"). Due to the above ownership structure, holdings for the Asset Managers are aggregated for purposes of this filing. Each Asset Manager is an investment adviser registered or authorized in its relevant jurisdiction and each furnishing investment advice to various fund, individual and/or institutional clients (collectively referred to herein as "Managed Portfolios"). As a result of its role as investment adviser or sub-adviser to the Managed Portfolios, JHIUS may be deemed to be the beneficial owner of 5,520,318 shares or 5.9% of the shares outstanding of Myovant Common Stock held by such Managed Portfolios. However, JHIUS does not have the right to receive any dividends from, or the proceeds from the sale of, the securities held in the Managed Portfolios and disclaims any ownership associated with such rights. Item 5. Ownership of Five Percent or Less of a Class Not applicable. Item 6. Ownership of More than Five Percent on Behalf of Another Person The Managed Portfolios, set forth in Item 4 above, have the right to receive all dividends from, and the proceeds from the sale of, the securities held in their respective accounts. The interest of any one such Managed Portfolio does not exceed 5% of the class of securities. These shares were acquired in the ordinary course of business, and not with the purpose of changing or influencing control of the Issuer. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company Intech, JHIUS, HGIL and JHIAIFML are indirect subsidiaries of Janus Henderson and are registered investment advisers furnishing investment advice to Managed Portfolios. Item 8. Identification and Classification of Members of the Group Not applicable. Item 9. Notice of Dissolution of Group Not applicable. Item 10. Certification By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired in the ordinary course of business and were not acquired for the purpose of and do not have the effect of changing or influencing the control of the issuer of such securities and were not acquired in connection with or as a participant in any transaction having such purposes or effect. SIGNATURES After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. JANUS HENDERSON GROUP PLC By /s/ Kristin Mariani Kristin Mariani, Head of North America Compliance, CCO Date 2/10/2022 Name/Title Attorney-In-Fact The original statement shall be signed by each person on whose behalf the statement is filed or his or her authorized representative. If the statement is signed on behalf of a person by his or her authorized representative other than an executive officer or general partner of the filing person, evidence of the representative's authority to sign on behalf of such person shall be filed with the statement (see Exhibit A), provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his or her signature. EXHIBIT A POWER OF ATTORNEY The undersigned, Janus Henderson Group plc ("the Company"), does hereby make, constitute and appoint each of Kristin Mariani and Caroline Barotti acting severally, as its true and lawful attorneys-in-fact, for the purpose of, from time to time, executing in its name and on its behalf, whether the Company individually or as representative of others, any and all documents, certificates, instruments, statements, other filings and amendments to the foregoing (collectively, "documents") determined by such person to be necessary or appropriate to comply with ownership or control-person reporting requirements imposed by any United States or non-United States governmental or regulatory authority, including, without limitation, Forms 13D, 13F, 13G and 13H and any amendments to any of the foregoing as may be required to be filed with the Securities and Exchange Commission, and delivering, furnishing or filing any such documents with the appropriate governmental, regulatory authority or other person, and giving and granting to each such attorney-in-fact power and authority to act in the premises as fully and to all intents and purposes as the Company might or could do if personally present by one of its authorized signatories, hereby ratifying and confirming all that said attorney-in-fact shall lawfully do or cause to be done by virtue hereof. Any such determination by an attorney-in-fact named herein shall be conclusively evidenced by such person's execution, delivery, furnishing or filing of the applicable document. This power of attorney shall be valid from the date hereof and shall remain in full force and effect until either revoked in writing by the Company, or, in respect of any attorney-in-fact named herein, until such person ceases to be an employee of the Company or one of its affiliates. IN WITNESS WHEREOF, the undersigned has caused this power of attorney to be executed as of this 30th day of September, 2021. Janus Henderson Group plc By: /s/ Bruce Koepfgen Name: Bruce Koepfgen Title: Executive Vice President, Head of North America
    Get the next $MYOV alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MYOV

    DatePrice TargetRatingAnalyst
    10/26/2022Outperform → In-line
    Evercore ISI
    8/9/2022$12.00 → $23.00Mkt Perform → Outperform
    SVB Leerink
    2/16/2022$21.00 → $19.00Market Perform
    SVB Leerink
    1/5/2022$23.00 → $21.00Market Perform
    SVB Leerink
    10/27/2021$24.00 → $23.00Market Perform
    SVB Leerink
    9/9/2021$24.00Market Perform
    SVB Leerink
    8/20/2021$18.00Neutral
    Goldman
    More analyst ratings

    $MYOV
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Myovant Sciences Announces Corporate Updates and Financial Results for Third Fiscal Quarter 2022

      Third fiscal quarter 2022 total revenue of $100.2 million; including net product revenue of $61.4 millionNet product revenue from U.S. sales of ORGOVYX® of $48.7 million in third fiscal quarter 2022, with sequential quarterly demand volume growth of 13% and cumulative patients estimated at 26,000 through December 2022Net product revenue from U.S. sales of MYFEMBREE® of $10.5 million in third fiscal quarter 2022, with sequential quarterly demand volume growth of 49% and cumulative patients estimated at 13,500 through December 2022Myovant remains well-capitalized with cash, cash equivalents, marketable securities, and amounts available under the Sumitomo Pharma Loan Agreement of $315.7 million

      1/26/23 4:05:00 PM ET
      $MYOV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Myovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08

      BASEL, Switzerland, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a biopharmaceutical company that aspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy, today announced that it approved equity awards for 18 new employees with a grant date of November 15, 2022 pursuant to Myovant's 2020 Inducement Plan. The equity awards were granted to the employees joining Myovant in accordance with NYSE's Listed Company Manual Rule 303A.08. The new employees received, in the aggregate, restricted stock units (RSUs) to purchase 149,300 common shares of Myovant. One-fourth of the shares underlying each employee'

      11/16/22 4:45:00 PM ET
      $MYOV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Myovant Sciences Appoints Ann Tomlin as Senior Vice President of Human Resources

      BASEL, Switzerland, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE:MYOV) today announced the appointment of Ann Tomlin as Senior Vice President of Human Resources. Beginning November 28, Ms. Tomlin will be responsible for developing talent solutions and human resources strategies across Myovant's global functions. She will serve as a member of the Executive Committee and will report to David Marek, Myovant's Chief Executive Officer. Ms. Tomlin has over 25 years of human resources experience with a demonstrated history of working in pharmaceutical and biotech organizations building strategies and solutions across organizational and people development, employee recruitment, busine

      11/16/22 6:45:00 AM ET
      $MYOV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MYOV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Myovant Sciences Ltd. (Amendment)

      SC 13D/A - Myovant Sciences Ltd. (0001679082) (Subject)

      3/10/23 9:29:56 AM ET
      $MYOV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Myovant Sciences Ltd.

      SC 13G - Myovant Sciences Ltd. (0001679082) (Subject)

      2/17/23 4:29:21 PM ET
      $MYOV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Myovant Sciences Ltd. (Amendment)

      SC 13G/A - Myovant Sciences Ltd. (0001679082) (Subject)

      2/14/23 4:17:11 PM ET
      $MYOV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MYOV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Myovant Sciences downgraded by Evercore ISI

      Evercore ISI downgraded Myovant Sciences from Outperform to In-line

      10/26/22 7:34:24 AM ET
      $MYOV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Myovant Sciences upgraded by SVB Leerink with a new price target

      SVB Leerink upgraded Myovant Sciences from Mkt Perform to Outperform and set a new price target of $23.00 from $12.00 previously

      8/9/22 7:22:43 AM ET
      $MYOV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVB Leerink reiterated coverage on Myovant Sciences with a new price target

      SVB Leerink reiterated coverage of Myovant Sciences with a rating of Market Perform and set a new price target of $19.00 from $21.00 previously

      2/16/22 5:19:55 AM ET
      $MYOV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MYOV
    SEC Filings

    See more
    • SEC Form 15-12G filed by Myovant Sciences Ltd.

      15-12G - Myovant Sciences Ltd. (0001679082) (Filer)

      3/20/23 1:58:45 PM ET
      $MYOV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Myovant Sciences Ltd.

      EFFECT - Myovant Sciences Ltd. (0001679082) (Filer)

      3/17/23 12:15:10 AM ET
      $MYOV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Myovant Sciences Ltd.

      EFFECT - Myovant Sciences Ltd. (0001679082) (Filer)

      3/17/23 12:15:07 AM ET
      $MYOV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MYOV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Valente Nancy returned 3,673 shares to the company, closing all direct ownership in the company (withholding obligation)

      4 - Myovant Sciences Ltd. (0001679082) (Issuer)

      3/10/23 9:32:52 AM ET
      $MYOV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Potter Myrtle S returned 3,673 shares to the company, closing all direct ownership in the company to satisfy tax liability

      4 - Myovant Sciences Ltd. (0001679082) (Issuer)

      3/10/23 9:32:18 AM ET
      $MYOV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Merendino Lauren returned 169,538 shares to the company, closing all direct ownership in the company to satisfy withholding tax

      4 - Myovant Sciences Ltd. (0001679082) (Issuer)

      3/10/23 9:31:44 AM ET
      $MYOV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MYOV
    Financials

    Live finance-specific insights

    See more

    $MYOV
    Leadership Updates

    Live Leadership Updates

    See more
    • Myovant Sciences Cancels Second Quarter Earnings Conference Call

      BASEL, Switzerland, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE:MYOV) ("Myovant") today announced the cancellation of its earnings conference call for the quarter ended September 30, 2022 that had originally been scheduled for October 26, 2022 at 5:00 p.m. Eastern Time. The call is being cancelled due to the announcement of the pending merger with Sumitovant Biopharma Ltd. ABOUT MYOVANT SCIENCES Myovant Sciences aspires to redefine care for women and men through purpose-driven science, empowering medicines, and transformative advocacy worldwide. Founded in 2016, Myovant has executed five successful Phase 3 clinical trials across hormone-sensitive oncology and women's health

      10/24/22 4:30:00 PM ET
      $MYOV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Myovant Sciences to Host Second Fiscal Quarter 2022 Earnings Conference Call at 5:00 p.m.

      BASEL, Switzerland, Oct. 14, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), today announced it will host a webcast and conference call to discuss corporate updates and financial results for its second fiscal quarter, ended September 30, 2022. The webcast and conference call will be held at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time on October 26, 2022. Investors and the general public may access the live webcast here. The live webcast can also be accessed by visiting the company's investor relations page of Myovant's website at: https://investors.myovant.com/. The webcast will be archived on the company website for approximately one year. ABOUT MYOVANT SCIENCES Myova

      10/14/22 6:45:00 AM ET
      $MYOV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Myovant Sciences and Pfizer Receive U.S. FDA Approval of MYFEMBREE®, a Once-Daily Treatment for the Management of Moderate to Severe Pain Associated With Endometriosis

      Data from the Phase 3 SPIRIT program showed MYFEMBREE reduced menstrual pain and non-menstrual pelvic pain in premenopausal women with endometriosis, and a loss of mean bone mineral density of less than 1% from baseline through one year of treatment Myovant and Pfizer will continue to jointly commercialize MYFEMBREE, with product available immediatelyMyovant to host conference call and webcast on Monday, August 8, 2022, at 8:30 a.m. Eastern Time / 5:30 a.m. Pacific Time BASEL, Switzerland and NEW YORK, Aug. 05, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE:MYOV) and Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved MYFEMBREE® (relugolix

      8/5/22 8:50:00 PM ET
      $MYOV
      $PFE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Myovant Sciences Appoints Ann Tomlin as Senior Vice President of Human Resources

      BASEL, Switzerland, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE:MYOV) today announced the appointment of Ann Tomlin as Senior Vice President of Human Resources. Beginning November 28, Ms. Tomlin will be responsible for developing talent solutions and human resources strategies across Myovant's global functions. She will serve as a member of the Executive Committee and will report to David Marek, Myovant's Chief Executive Officer. Ms. Tomlin has over 25 years of human resources experience with a demonstrated history of working in pharmaceutical and biotech organizations building strategies and solutions across organizational and people development, employee recruitment, busine

      11/16/22 6:45:00 AM ET
      $MYOV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Better Therapeutics Appoints Frank Karbe as Chief Executive Officer

      Better Therapeutics, Inc. (NASDAQ:BTTX), a prescription digital therapeutics (PDT) company developing nutritional cognitive behavioral therapy (nCBT) to address the root causes of cardiometabolic diseases, today announced that Frank Karbe will join the company as President and Chief Executive Officer and serve as a member of the Board of Directors starting July 5th, 2022. Current CEO and company co-founder, Kevin Appelbaum, will continue to serve in that role until then. "I'm thrilled to welcome Frank to the Better Therapeutics team," said outgoing CEO Kevin Appelbaum. "Over the past seven years, I have had the privilege of assembling and leading an extraordinarily talented and committed t

      6/7/22 7:30:00 AM ET
      $BTTX
      $EXEL
      $MYOV
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Phathom Pharmaceuticals Appoints Frank Karbe to its Board of Directors

      FLORHAM PARK, N.J., April 26, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced the appointment of Frank Karbe to its Board of Directors. Mr. Karbe, who most recently served as President and Chief Financial Officer of Myovant Sciences, Inc. (NYSE:MYOV), brings over twenty-five years of financial and life-sciences expertise to Phathom.    "We are thrilled to welcome Frank to our Board as we approach a critical inflection point for Phathom," said Terrie Curran, President and Chief Executive Officer of Phathom. "Frank's financial, business

      4/26/22 8:00:00 AM ET
      $EXEL
      $MYOV
      $PHAT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations